Javier Llorca

Javier Llorca

Auto-generated profile, based on publicly available information

Javier Llorca

Division of Preventive Medicine and Public Health, University of Cantabria School of Medicine, Santander, Spain

Research Focus & Metrics

Academic Career Length

26Years (2001-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 December 2015
Verified
Journal Article
Closed access
Tania Fernández-VillaTania Fernández-Villa
Tania Fernández-Villa
JOJuan Alguacil Ojeda
Juan Alguacil Ojeda
AGAna Almaraz Gómez
Ana Almaraz Gómez
JCJosé María Cancela Carral
José María Cancela Carral
AMAlba Marcos-Delgado
Alba Marcos-Delgado
Vicente MartínVicente Martín
Vicente Martín

1 April 2005 in Neuroepidemiology
Verified
Journal Article
Closed access
JLJavier Llorca
Javier Llorca
PGPaula Guerrero-Alonso
Paula Guerrero-Alonso
DPDolores Prieto-Salceda
Dolores Prieto-Salceda
Trends of multiple sclerosis mortality in Spain from 1951 to 1997 are examined. Age-adjusted mortality strongly decreased from 3.08 per 100,000 women in 1951–1967 to 0.59 in 1968–1980 (similar figures were obtained for men). This decrease seems to be due to an artifact produced by changes in codification of causes of death. An age-period-cohort analysis, limited to the period 1968–1997, showed that the mortality trend in Spain cannot be fully explained by year of death (period effect), but that a cohort (year of birth) effect is also necessary. An increase in mortality related with the cohort of birth was detected: people born after 1953 had double the risk of those born between 1938 and 1947, and four times the risk of those born between 1923 and 1932. Regarding the period effect, there is a decrease in mortality, probably due to improvements in life expectancy of multiple sclerosis patients.

1 June 2005 in Journal of Glaucoma
Verified
Journal Article
Closed access
JLJavier Llorca
Javier Llorca
FMFernando Martínez-Sanz
Fernando Martínez-Sanz
DPDolores Prieto-Salceda
Dolores Prieto-Salceda
CFConcepción Fariñas-Álvarez
Concepción Fariñas-Álvarez
MCM Verónica Chinchón
M Verónica Chinchón
MDMiguel Delgado-Rodríguez
Miguel Delgado-Rodríguez
Aim: To study the quality of controlled clinical trials on glaucoma. Methods: Two hundred and twenty-six clinical trials published between 1980 and 1999 were selected from seven international ophthalmological journals. Their quality was assessed by four researchers with epidemiological skills using a structured questionnaire. Results: Sample size was pre-estimated in 34 (15.0%) papers, which were of greater size (P = 0.05). Randomization was performed in 98.2% of the trials, although the procedure of randomization was scarcely reported. Masking was reported in 56.6% of the papers, and was more frequent in medical treatments (P < 0.001). The basal characteristics of the groups were compared in 139 papers (61.5%). Patient losses during the follow-up period were fully described in only 27 trials. Intention-to-treat analysis was used in 17 (7.7%) papers. Most trials reported P values, but a measure of effect (mean, proportion, or relative risk) appeared in only 16 trials (7.7%). Trials performed in the US more frequently compared baseline characteristics of the groups (P = 0.03), described the patient flow (P = 0.04), and used adequate statistical procedures (P = 0.03). Those trials that included a statistician or an epidemiologist among the authors were more commonly blinded (P = 0.06) and they always avoided the analyses of subgroups (P = 0.006). Several methodological issues have improved throughout the studied period. Conclusions: Several methodological characteristics should be improved when reporting a clinical trial on glaucoma. Using a checklist like that suggested by the CONSORT can help to achieve this.

1 January 2001 in Medicina Clinica
Verified
Journal Article
Closed access
MÁMaría Concepción Fariñas Álvarez
María Concepción Fariñas Álvarez
MFMaría Carmen Fariñas
María Carmen Fariñas
JLJavier Llorca
Javier Llorca
AMAlba Marcos-Delgado
Alba Marcos-Delgado